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Abstract 
Purpose: We aimed to investigate serum levels of matrix metalloproteinase-9 in both subarachnoid hemorrhage and 
control groups for prediction of cerebral vasospasm in this study.
Methods: Venous serum matrix metalloproteinase-9 levels were prospectively measured four times (days 1, 3, 7, and 
14) for 34 consecutive patients with subarachnoidal hemorrhage (n = 27) and for elective aneurysm clipping (control, 
n = 7).
Results: Vasospasm developed in 11/34 (32.4 %) patients between 3 and 10 days after subarachnoid hemorrhage 
(median 5.58 days), mean peak serum matrix metalloproteinase-9 compared with the non-vasospasm cohort. Matrix 
metalloproteinase-9 levels were higher in subarachnoid hemorrhage patients than in the controls.
Conclusion: Increased serum matrix metalloproteinase-9 could be an accurate biomarker to predict the onset of 
cerebral vasospasm after subarachnoid hemorrhage.
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Background
Subarachnoid hemorrhage (SAH) is a stroke subtype 
cause by blood leakage from a ruptured intracerebral 
aneurysm. It is characterized by sudden onset and is 
associated with high morbidity and mortality, often 
attributable to cerebral vasospasm (VS) with secondary 
cerebral ischemia (Dorsch 1995; Horstmann et al. 2006).
Delayed cerebral VS as defined angiographically occurs 
in up to 70 % of patients who present with SAH and leads 
to delayed ischemic deficits for 36  % of patients (Biller 
et  al. 1988). Matrix metalloproteinases (MMPs) can 
degrade extracellular matrix components in a variety of 
physiological and pathophysiological conditions such as 
stroke, intracerebral hemorrhage, and intracerebral aneu-
rysms (Montaner et al. 2001; Todor et al. 1998).
In this study, we aimed to determine the reliability of 
MMP-9 measurements in patients with acute SAH and 
patients without SAH but with incidental aneurysms, 
and also we investigated whether MMP-9 levels were 
related to SAH severity or VS occurrence and aneurysms.
Results
The clinical presentation [Hunt–Hess grade, Glas-
gow coma scale (GCS)] and radiological characteristics 
(Fisher grade, foci of hemorrhage) of 34 patients admit-
ted with or without SAH are shown in Table 1.
MMP-9 levels were significantly elevated in SAH group 
(27 patients) relative to the controls (7 patients). We 
measured MMP-9 levels in 27 SAH patients categorized 
by the presence or absence of VS as well as Hunt–Hess, 
Fisher, and GCS grades at admission. The overall pattern 
of higher MMP-9 levels was apparent in subjects with VS 
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and a higher Hunt–Hess score. MMP-9 levels remained 
substantially above the mean control level until day 14, 
when they tended to decrease.
Overall, 11 (32.4 %) of total 34 patients developed VS. 
Eight patients with SAH required emergency surgery. 
Two patients were treated with medical therapy, and 1 
patient who underwent elective aneurysm clipping devel-
oped VS.
Twenty-four (70.6  %) patients were discharged with 
normal neurological examination results. Ten (29.4  %) 
patients had neurological deficits [hemiparesis and pto-
sis (n = 6), and exitus (n = 4)], and 11 (32.4 %) patients 
developed VS. Clinical deterioration began between 
days 3 and 10 (median 5.58  days). A Chi square test 
revealed a significant interaction between the amount of 
blood in SAH (Fisher grade) and the development of VS 
(p = 0.035).
MMP-9 levels were higher in the SAH group com-
pared to the control group, but this was not significant 
(p  >  0.05). The same was true for the higher MMP-9 
levels in the VS group compared to the non-VS group 
(p > 0.05; Fig. 1).
Discussion
MMP-9 plays an important role in ischemic and hem-
orrhagic stroke, and serum levels significantly increase 
after SAH. MMP-9 is known to be secreted as an inactive 
preform that is quickly degraded after activation. In the 
present study, we attempted to demonstrate that serum 
MMP-9 concentrations can effectively predict the onset 
of delayed cerebral VS several days before TCD velocity 
changes or neurological deterioration.
There is no single treatment for VS because of its mul-
tifactorial etiology. The aim of treatment is to prevent 
the development of VS and protect the brain against 
ischemia. Zhang et  al. (2015) showed in rats that neu-
rovascular protection of astaxanthin in SAH is partly 
associated with the inhibition of MMP-9 expression and 
activity. In this respect, MMP-9 inhibition may help pre-
vention of VS in human SAH.
Lago et al. (2015) reported in the recent study that the 
infarcts were associated to SAH severity, SAH outcome 
and symptomatic vasospasm, and also metalloprotein-
ase-9 was higher in SAH patients than in controls, but it 
could not discriminate the infarct patients. Severity of the 
Table 1 Patient’s admission and discharge scores and aneurysmal features
Patients’GCS at admission 15 n = 24 (70.6 %)
14–10 n = 3 (8.7 %)
9–3 n = 7 (20.7 %)
Patients’GCS at discharge 15 n = 27 (79.4 %)
14–10 n = 3 (8.8 %)
9–3 n = 4 (11.8 %)
Patients’ Fischer grade at admission 1 (no blood) n = 9 (26.5 %)
2 (less than 1 mm) n = 6 (17.6 %)
3 (more than 1 mm) n = 12(35.3 %)
4 (intracerebral or ventricular hemorrhage n = 7 (20.6 %)
Patients’ Hunt Hess grade at admission 1 n = 20 (58.84 %)
2 n = 6 (17.6 %)
3 n = 4 (11.7 %)
4/5 n = 4 (11.7 %)
Foci hemorrhage Middle cerebral artery anevrsym n = 11 (32.4 %)
Anterior communican artery anevrsym n = 8 (23.5 %)
Posterior comminican anevrsym n = 4 (11.8 %)
Basilar type anevrsym n = 1 (2.9 %)
Carotid anevrsym n = 1 (2.9 %)
Arteriovenous malformation n = 3 (8.8 %)
Patients can not found the source of bleeding n = 6 (17.6 %)
The numbers of aneurysyms Single aneurysyms 19 (55.9 %)
Two aneurysyms 4 (11.8 %)
Three or more 2 (5.9 %)
AVM 3 (8.8 %)
No source of bleeding [but SAH (+)] 6 (17.6 %)
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initial insult, clinical status at admission, and Fisher grade 
were associated with increased MMP-9 concentration in 
our study. Patients who developed cerebral VS exhibited 
higher Hunt–Hess grade and Fisher grade, which is in 
agreement with an other study (Fisher et al. 1980).
Patients with higher Hunt–Hess scores on admission 
were more likely to be discharged with neurological defi-
cits (p =  0.016). MMP-9 levels were higher in the SAH 
group compared to the control group. Egashira et  al. 
(2015) reported that SAH causes blood brain barrier dis-
ruption and consequent injury in white matter. MMP-9 
plays an important role in those pathologies and could be 
a therapeutic target for SAH-induced white matter injury.
Overall, 11 patients (32.4  %) developed VS. Clinical 
deterioration began between the third and tenth days 
(mean 5.58  days). Among 18 patients who had SAH 
aneurysm due to clipping, 8 patients experienced VS. 
Nine patients without operation [SAH (+)] were fol-
lowed up medically, and two developed VS. One patient 
from the elective group experienced VS (surgical morbid-
ity). Four (14.81 %) patients in the SAH group died. These 
findings are consistent with what is reported in the litera-
ture (Awad et al. 1987; Muizelaar and Becker 1986).
The identification of patients with delayed cerebral 
VS before clinical deterioration might allow aggres-
sive and selective prophylactic intervention that could 
improve efficacy and minimize therapeutic complica-
tions and morbidity. Neurological recovery and improved 
outcomes associated with endovascular angioplasty or 
hypertensive, hemodilutional, or hypervolemic therapy 
after delayed cerebral VS might be dependent on early 
intervention (Medlock et al. 1992; Origitano et al. 1990).
The role of MMP-9 in VS is not clear (Minami et  al. 
1991). We rely on TCD and angiographic findings to 
measure increased velocities or identify stenotic lesions, 
respectively. However, TCD and angiographic results do 
not predict VS. The identification of a biomarker to pre-
dict VS would represent a significant advance in the field, 
allowing appropriate targeting of therapeutic prophylac-
tic measures.
Conclusion
Additional studies with larger numbers of patients who 
are treated several days earlier are needed to confirm 
the treatment of preclinical VS. This small prospective 
study indicates that MMP-9 might be a useful biomarker 
for identifying pre-ischemic delayed cerebral VS after 
SAH. Specifically, high serum MMP-9 concentrations 
may independently predict the onset of VS several days 
before ischemic deficits, potentially allowing acceler-
ated angiographic evaluation and aggressive prophylactic 
intervention.
Fig. 1 MMP-9 levels in the SAH group were higher than in the no-bleeding group, but this difference was not significant (p > 0.05)
Page 4 of 5Akpinar et al. SpringerPlus  (2016) 5:1153 
Methods
We analyzed serum samples of SAH patients seen at our 
department between January 2012 and July 2013. The 
study was approved by the ethics committee of Bakirkoy 
Psychiatric and Neurological Research and Training Hos-
pital, and all patients or their relatives gave informed 
consent. Patients’ characteristics were recorded, includ-
ing age, sex, and the presence of diabetes mellitus and 
hypertension (Table 2).
Consecutive patients admitted with or without aneu-
rysmal SAH (n = 27) or admitted for elective aneurysm 
clipping (n =  7) were enrolled. We planned to measure 
MMP-9 levels on days 1, 3, 7, and 14, which should span 
the period of increased VS risk.
All patients underwent TCD evaluations three times 
each week. The development of cerebral VS was confirmed 
angiographically by an independent neuroradiologist in 
patients who demonstrated a mean anterior cerebral artery 
or middle cerebral artery TCD velocity of >150  cm/s, or 
who exhibited neurological deficit onset after SAH.
Patients with aneurysm identified by angiography 
underwent surgery. Their risk factor profiles and Hunt–
Hess score at admission were ascertained. The occur-
rence of VS was determined by TCD or the onset of new 
focal neurological deficits.
Collected blood samples were centrifuged (4000×g), 
and the resulting supernatants were immediately frozen 
at −20 °C until analysis. Commercially available enzyme-
linked immunosorbent assay kits were used for quan-
titative determination of MMP-9 (Bender MedSystem, 
Vienna, Austria).
Statistical methods
We examined the reliability of MMP-9 determinations 
from the replicate samples. We calculated MMP-9 levels 
in all patients between days 1 and 14 (1, 3, 7, and 14). We 
used the exact Mann–Whitney distribution to establish 
whether the MMP levels were significantly between SAH 
patients and those patients without incidental aneurysm.
Correlations between Fisher grade and serum MMP-9 
levels were determined with multivariate logistic regres-
sion analyses, adjusting for patient age, sex, Hunt–Hess 
grade, Fisher grade, and GCS at admission.
Abbreviations
SAH: subarachnoid hemorrhage; GCS: Glasgow coma scale; MMPs: matrix 
metalloproteinase; TCD: transcranial Doppler; VS: vasospasm.
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